Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Building on some solid data, AbbVie and J&J today landed an FDA OK to sell a chemo-free combination of their BTK inhibitor Imbruvica with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
